Pipeline
Gamma Delta T Cell Therapy
Gamma delta (γδ) T cells represent a unique subset of T lymphocytes that function at the intersection of innate and adaptive immunity. Unlike conventional αβ T cells, γδ T cells operate independently of MHC-mediated antigen presentation and are being actively studied for their ability to detect cellular stress signals and abnormal antigen expression. SL BIO is advancing a proprietary immuno-oncology platform that utilizes allogeneic γδ T cells for potential application in immune redirection strategies. Ongoing preclinical studies are focused on evaluating the cytotoxic potential of γδ T cells across a range of tumor models—including both solid tumors and hematologic malignancies. This platform forms a foundational component of SL BIO’s translational research initiatives aimed at developing cellular therapies for difficult-to-treat cancers.
Note: All data referenced are derived from laboratory studies or animal models. Safety and efficacy in humans have not been established.
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
SL-GD001
Glioblastoma
SL-GD002
Pancreatic cancer
Current Status
Next Steps
SL-GD001 (GBM)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
SL-GD001
Glioblastoma
Current Status
Next Steps
SL-GD001 is an early-stage investigational program evaluating the potential of allogeneic gamma delta (γδ) T cells in the context of glioblastoma (GBM)—a highly aggressive and treatment-resistant primary brain tumor characterized by an immunosuppressive microenvironment. Current preclinical studies focus on assessing the ability of γδ T cells to engage tumor-associated markers and stimulate immune responses in both in vitro and in vivo GBM models. SL-GD001 is part of SL BIO’s broader initiative to explore non-genetically modified immune cell platforms for potential use in solid tumor immunotherapy.
Note: SL-GD001 is in the preclinical research phase. All findings are derived from laboratory-based experiments and animal models. Clinical efficacy and safety have not been established.
SL-GD002 (Pancreatic Cancer)
Program
Indication
Discovery
Pre-clinical
Phase 1
Phase 2
Phase 3
SL-GD002
Pancreatic cancer
Current Status
Next Steps
SL-GD002 is an early-stage investigational research program focused on evaluating allogeneic gamma delta (γδ) T cells in preclinical models of pancreatic cancer—a highly aggressive and immunosuppressive solid tumor with limited effective treatment options. The program is designed to assess the immunomodulatory activity and tumor-targeting potential of γδ T cells in both in vitro and in vivo systems. SL-GD002 contributes to SL BIO’s translational pipeline dedicated to advancing γδ T cell-based platforms for potential application in hard-to-treat malignancies.
Note: SL-GD002 is in the preclinical research stage. The results referenced are based on laboratory studies and animal models. Clinical efficacy and safety have not been established.